Cancer Therapeutics: Technology, Discovery, and Targeted Delivery Program

癌症治疗：技术、发现和靶向递送(CT) 研究计划 摘要 癌症治疗：技术、发现和靶向递送(CT)研究计划，由Larry领导 A.斯克拉尔博士和雷纳塔·帕斯奎里尼博士组成了一个由43人组成的多学科团队(27人为全职，16人为助理 成员)来自新墨西哥大学#年学院5个系的基础、翻译和临床调查人员 医学院，新墨西哥州立大学新墨西哥州立大学工程学院，新墨西哥州立大学药学院， 和我们的新墨西哥州癌症中心(UNCC)财团合作伙伴：洛夫莱斯呼吸研究所(LRRI) 以及桑迪亚(SNL)和洛斯阿拉莫斯国家实验室(LANL)。CT是一项新的联合国儿童基金会研究计划， 通过严格的计划规划和评估制定，以回应之前2010年NCI CCSG的批评 和外部咨询委员会(EAC)的指导。从癌症生物技术的起源开始 作为前癌症生物学和生物技术计划的组成部分，CT保留并获得了科学 擅长小分子发现和药物再利用，多肽和抗体的组合靶向 噬菌体展示文库，基于纳米颗粒和病毒样颗粒(VLP)的药物输送，以及成像和 同位素。在之前的资助期间(从1/1/10到9/1/2014)，CT计划成员发表了336份原创 同行评审的文章和评论(37%是方案内的，24%是方案间的)，并参与了6 由调查员发起的试验。截至2014年9月1日，CT的年度直接成本为16,076,676美元，其中14,196,182美元 是经过同行审查的直接资金，3,105,330美元来自NCI。斯克拉尔博士是一位白细胞生物学专家， 药物发现和/或再利用，而帕斯奎尼博士是血管靶向方面的专家，其关键工作是 带有噬菌体展示的vivo已经导致了广泛的临床前和临床应用；两位领导者都很有经验 在翻译和商业化方面。计算机技术贡献了联东特派团的大部分知识产权以及 10家生物技术或制药初创公司。该计划受益于技术专业知识 联东综合团、解放卢旺达民主力量、民族解放力量和民族解放力量之间的伙伴关系。通过战略招聘新人才 教师和基础设施重组，CT翻译管道正在通过以下方式扩展：i)小分子 发现和药物再利用、流式细胞仪技术和化学信息学；二)组合靶向 通过选择多肽和抗体噬菌体展示文库；iii)偶联的靶向配体定向递送 材料纳米制造、预测数学方法论和分子成像；以及iv)早期翻译 进入临床应用。注意到CT成员持有的多学科、多调查员方案赠款 包括支持转化性研究和临床干预的大型NIH、NCI和国防部资金。近期 医生-科学家和临床研究人员将领导目前和计划的早期 研究人员发起的临床试验。CT的总体目标是发现、开发和翻译创新平台 通过使用生物工程、生物技术、 纳米技术、噬菌体展示、数学和信息学作为早期介入性临床试验的基础。

CANCER THERAPEUTICS: TECHNOLOGY, DISCOVERY & TARGETED DELIVERY (CT) RESEARCH PROGRAM ABSTRACT The Cancer Therapeutics: Technology, Discovery and Targeted Delivery (CT) Research Program, led by Larry A. Sklar, PhD and Renata Pasqualini, PhD, consists of a multidisciplinary team of 43 (27 full and 16 associate members) of basic, translational and clinical investigators assembled from 5 Departments in the UNM School of Medicine, 2 in the UNM College of Engineering, the UNM College of Pharmacy, New Mexico State University, and our UNM Cancer Center (UNMCC) consortium partners: Lovelace Respiratory Research Institute (LRRI) and Sandia (SNL) and Los Alamos National (LANL) Laboratories. CT is a new UNMCC Research Program, developed through rigorous program planning and evaluation in response to the prior 2010 NCI CCSG critique and guidance from the External Advisory Committee (EAC). Building from its origins in the Cancer Biotechnology component of the former Cancer Biology & Biotechnology Program, CT has retained and acquired scientific expertise in small molecule discovery and drug repurposing, combinatorial targeting of peptide and antibody phage display libraries, nanoparticle and virus-like particle (VLP)-based drug delivery, as well as imaging and isotopes. During the prior funding period (from 1/1/10 to 9/1/2014), CT program members published 336 original peer-reviewed articles and reviews (37% intra-programmatic and 24% inter-programmatic) and participated in 6 investigator-initiated trials. As of 9/1/14, CT funding is $16,076,676 in annual direct costs, of which $14,196,182 is peer-reviewed direct funding and $3,105,330 is from the NCI. Dr. Sklar is an expert in leukocyte biology and drug discovery and/or repurposing while Dr. Pasqualini is an expert in vascular targeting whose pivotal work in vivo with phage display has led to extensive pre-clinical and clinical applications; both leaders are experienced in translation and commercialization. CT has contributed to the bulk of UNMCC intellectual property as well as 10 biotechnology or pharmaceutical start-up companies. The Program benefits from the technological expertise in partnerships among the UNMCC, LRRI, SNL and LANL. Through the strategic recruitment of new talented faculty and infrastructure reorganization, the CT translational pipeline is expanding through: i) small molecule discovery and drug repurposing, flow cytometry technology and cheminformatics; ii) combinatorial targeting through selection of peptide and antibody phage display libraries; iii) targeted ligand-directed delivery coupled to material nanofabrication, predictive mathematical methodology, and molecular imaging; and iv) early translation into clinical application. Noted multidisciplinary, multi-investigator programmatic grants held by CT members include large NIH, NCI and DOD funds supporting translational investigations and clinical interventions. Recent physician-scientist and clinical investigator recruits will lead the current and planned portfolio of early investigator-initiated clinical trials. CT's overall goal is to discover, develop and translate innovative platform technologies into cancer diagnostic and therapeutic applications by using bioengineering, biotechnology, nanotechnology, phage display, mathematics and informatics as the basis for early interventional clinical trials.